kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - Öll önnur lækningavörur - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
hemgenix
csl behring gmbh - etranacogene dezaparvovec - hemophilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - Ónæmisbælandi lyf - treatment of moderate-to-severe plaque psoriasis in adults.
fosrenol tuggutafla 750 mg
takeda pharmaceuticals international ag ireland branch - lanthanum karbónat - tuggutafla - 750 mg
fosrenol tuggutafla 500 mg
takeda pharmaceuticals international ag ireland branch - lanthanum karbónat - tuggutafla - 500 mg
kairasec tafla 8 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg
valsartan jubilant filmuhúðuð tafla 80 mg
jubilant pharmaceuticals nv - valsartanum inn - filmuhúðuð tafla - 80 mg
kairasec tafla 16 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg
daivobet hlaup 50 míkróg/g /0,5 mg/g
leo pharma a/s* - calcipotriolum inn; betamethasonum díprópíónat - hlaup - 50 míkróg/g /0,5 mg/g